Intellia Therapeutics (NTLA) CSO awarded options and RSUs

Rhea-AI Filing Summary

Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes received new equity awards. On March 1, 2026, she was granted stock options for 56,000 shares of Intellia common stock at an exercise price of $0.00 per share and 39,200 shares of common stock as a grant.

The common stock grant is based on restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The option grant vests with 33% on January 1, 2027, and the remaining 67% in 24 substantially equal monthly installments after that date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Schultes Birgit C

Role EVP, Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	56,000	$0.00	--
Grant/Award	Common Stock	39,200	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 56,000 shares (Direct); Common Stock — 137,733 shares (Direct)

Footnotes (1)

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schultes Birgit C

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		39,200	A	$0	137,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.78	03/01/2026		A		56,000		(2)	02/29/2036	Common Stock	56,000	$0	56,000	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	James Basta, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NTLA executive Birgit C. Schultes report?

Birgit C. Schultes reported receiving equity awards, not open-market trades. She was granted 56,000 stock options and 39,200 shares of common stock linked to restricted stock units, all dated March 1, 2026, as part of her compensation at Intellia Therapeutics.

How many stock options did NTLA grant to Birgit C. Schultes?

Intellia Therapeutics granted Birgit C. Schultes stock options for 56,000 shares of common stock. These options carry an exercise price of $0.00 per share and vest over time, with one-third vesting first and the remaining two-thirds vesting in equal monthly installments.

What common stock grant did Birgit C. Schultes receive from Intellia (NTLA)?

Birgit C. Schultes received a grant of 39,200 shares of Intellia common stock. This award is based on restricted stock units, each unit representing a contingent right to receive one share of common stock, providing time-based equity compensation rather than an immediate cash transaction.

How do Birgit C. Schultes’s NTLA stock options vest over time?

The stock options granted to Birgit C. Schultes vest on a time-based schedule. Thirty-three percent vest on January 1, 2027, while the remaining 67% vest in 24 substantially equal monthly installments thereafter, creating a multi‑year incentive and retention structure.

Are Birgit C. Schultes’s NTLA Form 4 transactions buys or grants?

The reported transactions are equity grants, not open-market purchases. Both the 56,000 stock options and 39,200 common shares were acquired through compensation awards, reflected by transaction code “A” for grant, award, or other acquisition in the Form 4 filing.

What is Birgit C. Schultes’s ownership after the NTLA common stock grant?

Following the common stock grant, Birgit C. Schultes is shown as directly owning 137,733 shares of Intellia common stock. This figure in the Form 4 includes the newly awarded 39,200 shares tied to restricted stock units, increasing her reported direct equity stake.